Castle Biosciences (NASDAQ:CSTL) Stock: Insider Tobin Juvenal Sells 2,828 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 2,828 shares of the company’s stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $35.04, for a total transaction of $99,093.12. Following the completion of the sale, the insider directly owned 32,737 shares in the company, valued at $1,147,104.48. This trade represents a 7.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

Shares of CSTL traded up $0.51 during mid-day trading on Thursday, reaching $34.50. 440,800 shares of the company’s stock were exchanged, compared to its average volume of 398,699. The company has a quick ratio of 5.12, a current ratio of 5.28 and a debt-to-equity ratio of 0.01. The company has a 50-day simple moving average of $34.30 and a two-hundred day simple moving average of $28.42. Castle Biosciences, Inc. has a 52-week low of $17.72 and a 52-week high of $44.28. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -44.81 and a beta of 1.00.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.22. The firm had revenue of $101.95 million during the quarter, compared to the consensus estimate of $92.76 million. Castle Biosciences had a negative return on equity of 4.89% and a negative net margin of 6.10%. On average, sell-side analysts predict that Castle Biosciences, Inc. will post -0.83 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on CSTL shares. Wall Street Zen upgraded Castle Biosciences from a “hold” rating to a “buy” rating in a research report on Sunday, November 1st. Robert W. Baird lifted their price objective on Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a research report on Monday. BTIG Research boosted their target price on shares of Castle Biosciences from $44.00 to $52.00 and gave the company a “buy” rating in a research note on Monday. Mizuho assumed coverage on shares of Castle Biosciences in a report on Thursday, October 29th. They issued an “outperform” rating and a $60.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Castle Biosciences in a research note on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $46.50.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CSTL. Advisors Capital Management LLC purchased a new stake in shares of Castle Biosciences in the second quarter valued at $5,681,000. BlackRock Inc. purchased a new position in Castle Biosciences during the second quarter worth about $78,513,000. Bank of New York Mellon Corp purchased a new position in Castle Biosciences during the second quarter worth about $2,338,000. Empowered Funds LLC acquired a new stake in Castle Biosciences in the 2nd quarter worth about $3,395,000. Finally, Quantinno Capital Management LP boosted its stake in Castle Biosciences by 387.3% in the 1st quarter. Quantinno Capital Management LP now owns 45,476 shares of the company’s stock worth $1,116,000 after buying an additional 36,144 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests intended to help physicians make personalized treatment and care decisions. Its tests analyze biological features of tissue to provide information about disease behavior and patient risk. The company’s portfolio includes DecisionDx tests for conditions such as cutaneous melanoma, cutaneous squamous cell carcinoma and uveal melanoma. It also offers TissueCypher, a test designed to assess progression risk in patients with Barrett’s esophagus.